Hepatology











Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).


The patient was a 63-year-old male diagnosed with hepatocellular carcinoma (HCC) in April 2013, presenting with two lesions – 7.7 and 3.5 cm in segment 4 and segment 8, respectively. He underwent two rounds of transarterial chemoembolization (TACE) in May and June 2013, with good response. In September 2013, he underwent hepatic wedge resection for both lesions.


Minimal monitoring is feasible in patients with active hepatitis C virus (HCV) infection treated with sofosbuvir/velpatasvir (SOF/VEL), with high rates of sustained virologic response (SVR) reported, including in patients with novel HCV subtypes, according to new data from the phase IV MINMON study presented at IDDF 2023.





